Barclays’s Charles River Laboratories CRL Stock Holding History

Barclays’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,200	Closed	-$170K	–	6762
2019 Q2	$170K	Hold	1,200	–	–	﹤0.01%	5260
2019 Q1	$174K	Sell	1,200 -700	-37%	-$92K	﹤0.01%	4925
2018 Q4	$215K	Buy	+1,900	New	+$238K	﹤0.01%	4523
2014 Q3	–	Sell	-100	Closed	-$5K	–	7669
2014 Q2	$5K	Hold	100	–	–	﹤0.01%	7106
2014 Q1	$6K	Buy	+100	New	+$5.83K	﹤0.01%	7127
2013 Q4	–	Sell	-50,000	Closed	-$2.3M	–	7544
2013 Q3	$2.3M	Buy	+50,000	New	+$2.29M	﹤0.01%	2412

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Barclays's CRL Position: Q2 2026 in Review

Barclays reduced its Charles River Laboratories (CRL) stake by 77% in Q2 2026, selling an estimated $32.2M and leaving 53,896 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Barclays first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. The position peaked at $40.5M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Barclays held 53,896 shares of Charles River Laboratories worth $12.2M as of Q2 2026.
Barclays sold 181,040 Charles River Laboratories shares in Q2 2026, an estimated $32.2M.
Charles River Laboratories made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1378 holding.
Barclays first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
Barclays's Charles River Laboratories position peaked at $40.5M in Q1 2026.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.